Completed

SCH 56592 vs Fluconazole for Oropharyngeal Candidiasis in HIV-Positive Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Posaconazole

+ Fluconazole

Drug
Who is being recruted

Blood-Borne Infections+21

+ Urogenital Diseases

+ Genital Diseases

Over 18 Years
+16 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 3
Interventional
Study Start: August 1998
See protocol details

Summary

Principal SponsorSchering-Plough
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Study start date: August 1, 1998

Actual date on which the first participant was enrolled.

Patients receive SCH 56592 oral suspension or fluconazole suspension for 14 days. Patients remain on study for 44 days total and are monitored for safety and efficacy of study treatment.

NCT00002446
Principal SponsorSchering-Plough
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

300 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesBacterial Infections and MycosesCandidiasisCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsStomatognathic DiseasesMouth DiseasesMycosesOpportunistic InfectionsOtorhinolaryngologic DiseasesRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsCandidiasis, OralPharyngeal DiseasesHIV InfectionsAIDS-Related Opportunistic Infections

Criteria

6 inclusion criteria required to participate
Are expected to live for at least 2 months.
Are able to take study medication and return for clinic visits during the study.
Agree to practice sexual abstinence or use effective barrier methods of birth control (e.g., condoms).
Are at least 18 years old.
Show More Criteria
10 exclusion criteria prevent from participating
Cannot take medications by mouth.
Are allergic to azole drugs.
Have certain medical conditions.
Have received SCH 56592 within 3 months prior to study entry.
Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 18 locations

East Bay AIDS Ctr

Berkeley, United StatesOpen East Bay AIDS Ctr in Google Maps

ViRx Inc

San Francisco, United States

Kaiser Foundation Hospital

San Francisco, United States

Infectious Disease and AIDS Clinic

Denver, United States
Completed18 Study Centers